T he majority of patients with inflammatory bowel disease (IBD) are diagnosed during the ages of 15 to 35 years, coinciding with the peak years of fertility and pregnancy, 1 and therefore questions regarding reproductive outcomes are relevant. Recent studies have suggested that disease activity in pregnant women with IBD is associated with adverse birth outcomes but the results have been conflicting. [2] [3] [4] [5] [6] In studies of IBD and birth outcomes, it is often difficult to separate out the effects of disease activity, medication use, and IBD severity. 7 Most recent studies on birth outcomes in women with IBD have included women with varying degrees of disease severity and immunosuppressive medications, thereby making the interpretations difficult. [8] [9] [10] [11] [12] Although it is relevant to study women who are not on immunosuppressive medications or who do not have moderate or severe disease, it is also highly relevant to study those with a more severe disease course. Although these more severely diseased patients are just a subset of the women with IBD in general, they are the patients who require the most care.
To examine this group of women with IBD who are more likely to do poorly during pregnancy, we studied a cohort of Danish women with moderate to severe IBD who had all been treated at some time during pregnancy with anti-tumor necrosis factor alpha (anti-TNF-a) therapy. In Denmark, anti-TNF-a therapy is given to patients with IBD who have moderate to severe disease; this is according to the European Crohn's and Colitis Organisation guidelines and to the Danish national guidelines. [13] [14] [15] Using these criteria, we were able to identify a nationwide cohort of women with moderate to severe IBD course, and within this cohort, our goal was to examine the effect of disease activity on adverse birth outcomes. The outcomes were preterm birth, low birth weight (LBW), and congenital abnormalities (CA). This is so far the largest study on the impact of disease activity during pregnancy in a cohort of women with similar underlying moderate to severe disease course.
MATERIALS AND METHODS

A Nationwide Cohort of Births by Women with Moderate to Severe IBD
We established a study population of all childbirths by Danish women with IBD who received anti-TNF-a therapy at least once during the pregnancy and/or 90 days before conception ("the pregnancy period"), i.e. anti-TNF-a therapy made women eligible for the study population. Identification of women with IBD and their childbirths derived from data from the National Patient Registry (NPR), the Medical Birth Registry (MBR), and by linkage of data via the unique civil identification number (civil personal registration). The NPR includes records of all discharges from Danish hospitals since 1977 and all outpatient visits since 1994, 16 hospital, date of admission and discharge, procedures performed, and up to 20 discharge diagnoses based on the International Classification of Diseases-10. The MBR includes information on all births in Denmark since January 1, 1973, 17 and it links the mother and child through the civil personal registration.
From the NPR, we identified every woman with a discharge diagnosis of ulcerative colitis (UC) or Crohn's disease (CD) (International Classification of Diseases-10 codes K50 for CD, K51 for UC), and thereafter, we identified all births by these women. We only selected births by women who had received anti-TNF-a therapy at least once during the pregnancy period (procedure codes in the NPR: BOHJ18A and ML04AB), and as the first pregnant woman was treated with anti-TNF-a therapy in 2005, we thus included childbirths from January 1, 2005, through December 31 2014 (N ¼ 263 childbirths by 258 pregnancies). The date of conception was based on the information from the MBR according to ultrasound measurement of the gestational age. After identification, every eligible woman had her medical records reviewed thoroughly for clinical details.
Information on Clinical Details from Medical Records
Each patient file was reviewed to collect data on clinical details such as disease activity according to trimesters and concomitant medical therapy. The overall information included assessment of the validity of the diagnoses of UC and CD, date of the UC/CD diagnosis, former UC/CD related surgery, and the type of anti-TNF-a therapy. According to each trimester and the preconception period, we identified the type of anti-TNF-a therapy, total number of treatments during each period, and details about co-medication (corticosteroids, thiopurines, and mesalazine). When present, we retrieved information on fecal calprotectin (FC) levels according to each trimester. Information on disease activity was retrieved according to each trimester. Physicians routinely registered the Harvey Bradshaw Index (HBI) 18 for patients with CD and the Simple Clinical Colitis Activity Index (SCCAI) 19 in patients with UC at each visit. Disease activity was defined as HBI score .4 and SCCAI score .2. Since HBI and SCCAI were available in around 50% of patient visits, all charts were reviewed for an additional assessment of IBD as follows: (1) inactive disease: #2 bowel movements per day, and absence of blood/pus in the stools, no abdominal pain, and no systemic symptoms such as fewer or weight loss; (2) mild activity: 2 to 4 bowel movements per day and/or blood/pus in the stools and/or mild abdominal pain less than daily, no systemic symptoms such as fewer or weight loss; (3) moderate to severe activity: $4 bowel movements daily and/or passage of blood/pus daily and/or abdominal pain either severe or daily, with or without systemic symptoms such as fewer or weight loss. This approximated scoring system has been used in other highly cited studies of IBD during pregnancy and is a reasonable alternative when the HBI and SCCAI scoring systems are absent. 4, 20, 21 We excluded 32 patients due to lack of treatment with anti-TNF-a therapy/misclassification of the diagnosis, one record could not be located, and another we were not permitted to review. As multiple births in general have a higher risk of adverse birth outcomes we only included singletons, 22 and thus we excluded 5 multiple births.
Information from the MBR
From the MBR, we included maternal variables associated to each identified birth: date of birth, parity, weight, and smoking in the first trimester. Correspondingly, we included variables for each identified child: birth weight, gestational age, and codes for CA.
Outcome Definitions
The outcomes were (1) LBW as birth weight below 2500 g, (2) preterm birth defined as birth less than 37 completed pregnancy weeks, and (3) CAs.
Statistical Analyses
The association between disease activity during pregnancy and adverse birth outcomes was examined in our cohort of women with moderate to severe disease course. The exposed cohort constituted women who experienced disease activity (mild or moderate-severe or HBI .4 or SSCAI .2) at least once during the pregnancy period. The unexposed cohort constituted women without disease activity during the pregnancy period. Every pregnancy was included as an independent event.
We obtained contingency tables according to exposed and unexposed cohorts. In the descriptive table for birth outcomes, we used a 2-sided t test.
We estimated the relative risk estimates (prevalence odds ratio [OR] with 95% confidence interval [95% CI]) for the adverse birth outcomes. Logistic regression analyses were used to estimate the relative risk estimate for adverse birth outcomes associated with disease activity in women with IBD, adjusted for potential confounders. The following confounders were taken into consideration: mother's age (continuous variable), Charlson comorbidity index (no comorbidity/comorbidity index $1), 23 smoking (yes/no), parity (primiparous or multiparous), and drug therapy (yes/no to use of mesalazine, steroids, and/or thiopurines). The risk of LBW was also adjusted for gestational age (continuous variable). As Charlson index and parity did not change the relative risk estimates, these variables were left out of the final model. Due to lack of power, we did not perform adjusted analyses according to adverse birth outcomes for UC and CD separately. Only crude ORs were thus given for adverse birth outcomes according to UC and CD. In subanalysis 1, we stratified our analyses according to the type of underlying disease of UC or CD and examined the impact of disease activity on birth outcomes.
In subanalysis 2, we estimated the impact of those with the highest degree of disease activity (moderate-severe activity or HBI score $8 or SCCAI score $6) on adverse birth outcomes. The unexposed group in this analysis was still those women with IBD without disease activity during pregnancy. We only presented the crude OR in the subanalysis due to the small groups.
All calculations were performed using STATA Release 14.0 (StataCorp, College Station, TX).
Approvals
The study is approved by the Danish Data Protection Agency (j. nr. 2012-41-0022) according to the Danish law. The National Danish Board of Health approved the collection of data from the patient records (j. nr 3-3013-597/1).
RESULTS
All included, 219 children were live-born. Several women gave birth to more than one singleton child (27 women gave birth to 2 singletons and 2 women to 3 singletons).
Maternal Factors
The baseline characteristics for the exposed and unexposed cohorts are shown in Table 1 . Among the 219 women, 144 (65.8%) experienced clinical disease activity during pregnancy (exposed cohort) and 75 (34.3%) did not (unexposed cohort). Of the 144 women with disease activity, 55 (25.1%) were categorized with mild disease and 89 (40.6%) with moderate to severe disease. There were no major differences between the 2 cohorts according to age, parity, body mass index, smoking, comorbidity, duration of IBD, and the use of infliximab and adalimumab. The 3 most-common periods for maternal disease activity were the preconception period, first trimester, and first + second + third trimester (Table 1) . In those women with disease activity, the median FC level was 731 mg/kg (25%-75% percentiles 215-1800), and in those women without disease activity, the median level of FC was 157 mg/kg (25%-75% percentiles 80-420), and this difference was significant (P ¼ 0.0002). FC was measured 71 times in the exposed cohort and only 24 times in the unexposed cohort.
Examining women with UC and CD separately, we found a similar distribution of basic characteristics (data not shown). In women with UC, 9 (18.0%) remained in remission during pregnancy, whereas 41 (82.0%) experienced clinical disease activity. Of these 41 women, 10 (20%) experienced mild disease activity and 31 (62%) moderate to severe disease activity ( Table 1 ). In women with CD, 66 (39.1%) remained in remission, whereas 103 (60.9%) experienced clinical disease activity during the pregnancy period. Of these, 45 (26.6%) experienced mild disease activity and 58 (34.3%) moderate to severe disease activity (Table 1) .
Birth Outcomes in Children of Women with Disease Activity Compared with Women Without Disease Activity
The mean gestational age and birth weight are given in Table 2 according to maternal disease activity. Overall, the difference in the mean birth weight between the exposed and unexposed was 248 g (P ¼ 0.003). The largest difference in birth weight was seen in women with UC, where the mean birth weight in children of women with disease activity was 3080 g versus 3659 g in children of women without disease activity (P ¼ 0.02). Overall, the mean gestational age was lower in children of women with disease activity compared with women without disease activity (38.6 versus 39.5 weeks, P ¼ 0.002). For women with UC, the gestational age was 37.6 weeks in children of women with disease activity versus 39.7 weeks in children of women without disease activity (P ¼ 0.05). Table 3 shows the crude and adjusted ORs for LBW, preterm birth, and CAs for the women with disease activity relative to those without disease activity. Disease activity was associated with an increased risk of LBW and preterm birth, adjusted ORs 2.05 (95% CI, 0.37-11.35) and 2.64 (95% CI, 0.85-8.17), respectively. Table 4 shows the crude ORs in subanalysis 1, i.e. the stratified analysis according to UC and CD. In women with UC having disease activity, we found that 19.5% gave birth to a child with LBW and 29.3% gave birth preterm. Among women with UC without disease activity, no children were born with LBW or preterm. Among women with CD, disease activity was associated with an increased risk of LBW and preterm birth, but none were significantly increased.
The risk of CAs was not significantly increased (Table 3  and 4) . We found 15 CAs in children by women with UC and CD (2 ankyloglossia, 2 cryptorchidism, 2 congenital hip luxation, 2 CAs of the foot, 1 hypospadia penis, 1 cranosyntosis, one CA of the tongue without specification, and 4 different craniosynostosis, heart malformations).
In subanalysis 2, examining the effect of moderate to severe disease activity on birth outcomes, the crude ORs for LBW and preterm birth were 4.11 (95% CI, 0.88-23.55) and 3.60 (95% CI, 1.14-11.36), respectively (Table 5) .
DISCUSSION
This study is the first to report important birth outcomes such as LBW, preterm birth, and CAs in a nationwide cohort of children born to women with a moderate to severe IBD course (as all women were treated with anti-TNF-a therapy during the pregnancy period). In our study, we showed that 65.8% of the women with moderate to severe IBD experienced disease activity during pregnancy and 40.6% of those had moderate to severe disease. In those women with the highest degree of disease activity, the risk of preterm birth was increased 3 to 4 folds. A negative impact of disease activity, in general, on birth outcomes was seen particularly for women with UC. The mean birth weight and mean gestational age were significantly lower in children of women with UC having disease activity than in children of women without disease activity. In women with UC with disease activity, 19.5% had a child with LBW and 29.3% of the children were born preterm. In UC women without disease activity, no child was born preterm or with LBW. One of the main strengths of our study is that the results are based on a nationwide cohort of women with moderate to severe IBD. Furthermore, it includes precise individual clinical data based on the review of medical records, allowing us to validate the diagnosis, the accurate comedication, and the accurate degree/categorization of the disease activity according to each trimester. Information bias was prevented as data on birth outcomes were included independent of information on disease activity during pregnancy, and selection bias was prevented as we had complete follow-up on all children. Another important strength is our ability to do subanalysis according to the degree of disease activity.
The study also has limitations. We only considered pregnancies that ended in a live-birth and did not consider early adverse pregnancy outcomes such as miscarriages/abortions. Therefore, we might have underestimated the true relative risk of adverse outcomes due to disease activity. We also considered the validity of disease activity scores. First, disease activity indexes have never been validated in pregnant women, and second, the clinicians often used written details about patients' symptoms instead of HBI/SSCAI scores (missing HBI/SSCAI scores in around 50% of the patient visits). To compensate for the missing HBI/SCCAI scores, we, therefore, choose a scoring system that had been used on pregnant women in other studies. 4, 20, 21 Information on FC was collected according to the trimester of concomitant disease activity, and the levels of FC in our exposed and unexposed cohort certainly supported the high validity of our categorization of those with and without clinical disease activity. Although our study is based on a nationwide cohort, we are still challenged on the statistical power of our estimates due to low prevalence of adverse birth outcomes. This article reports on only those women with moderate to severe IBD, and therefore, our results do not apply to the general population of Danish patients with IBD. 24 This is most likely the reason for both the higher proportion of women with disease activity during pregnancy, and the high proportion of those with adverse birth outcomes in our study, compared with other studies. 8, 11, [25] [26] [27] Our results are in line with an earlier study which demonstrated that nonpregnant patients with CD who were treated with anti-TNFa therapy had a significantly higher proportion of disease activity -as high as 86.3%. 28 The reason for initiating anti-TNF-a therapy in Denmark is based on the severity of IBD, a consequence of insufficient response to conventional medical therapies, and/or due to prophylactic considerations, especially during pregnancy. Therefore, it is important to underline that our results cannot necessarily be applied to women with UC and CD with a milder disease course where anti-TNF-a therapy is not indicated.
Anti-TNF-a therapy was initially discontinued in Denmark when pregnancy occurred due to the fear of teratogenicity. However, based on case series reporting normal birth outcomes 24, 25, 29, 30 and due to class B recommendation from the U.S. Food and Drug Administration, Danish clinicians have used anti-TNF-a therapy to treat moderate to severe IBD during pregnancy since 2005. Over the past decade, there have been few case studies and case series on the association between anti-TNFa therapy and adverse birth outcomes. Recently, a few larger studies have been published, but due to the relatively small populations, the question regarding increased risk of adverse birth outcome remains uncertain. 6, 24, 25, [29] [30] [31] [32] [33] [34] Preliminary data from the Pregnancy in Inflammatory Bowel Disease and Neonatal Outcomes study found an increased risk of preterm birth among women on combination therapy (OR: 2.4; 95% CI, 1.3-4.3). 9 Earlier studies have examined the association between disease activity and adverse birth outcomes in women with IBD. 8, 11, 12, 26, 27, 35, 36 In these studies, the women had been treated with different medications in pregnancy, had all types of underlying disease severity, and had a variety of outcomes. Bortoli et al 11 presented 332 pregnant women with IBD and found no correlation between birth outcomes and disease activity compared with healthy controls. The majority of the women remained in remission during the pregnancy. In contrast to our findings, Pedersen et al 27 found no significant impact of disease activity on birth outcomes in pregnant women with disease activity compared 5 found that disease activity at conception increased the risk of disease relapse during pregnancy. However, only a third of patients were on anti-TNF-a therapy, and the authors did not stratify for anti-TNF-a therapy use. 5 Our results regarding CAs are reassuring. A total of 15 children were born with CAs and the types of CAs showed no distinct pattern. One former nationwide study has examined CAs in women treated with anti-TNF-a therapy during pregnancy and found a slightly increased risk, 1.32 (95% CI, 0.93-1.82), but the heterogeneity of the observed CAs did not indicate a common etiology. 37 The study did not take disease activity into consideration. 37 For the first time, we have examined adverse birth outcomes according to disease activity in a national cohort of women with moderate to severe underlying IBD (anti-TNF-a therapy had been indicated for all in the pregnancy period). We found that disease activity was associated with a high proportion of adverse birth outcomes in women with IBD treated with anti-TNF-a therapy in the pregnancy period, and particularly, women with active UC had high proportions of adverse birth outcomes. We also found a significantly increased risk of preterm birth in the subgroup of women with moderate to severe disease activity during pregnancy. As this is the first nationwide study based on a population of women treated with anti-TNF-a therapy in pregnancy, our results should be confirmed in other study populations and settings. Our results also illustrate the complexity of factors that have to be taken into account when examining birth outcomes in these women with moderate to severe IBD. To assess the precise impact of disease activity on adverse birth outcomes, it is thus crucial to have valid information on factors such as the type of underlying disease, different medications, timing between disease activity and treatment, and important maternal factors. Based on our results, we suggest that physicians should be especially vigilant when caring for this population of patients with IBD during pregnancy. 
